$42.61+1.9%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 9, 2026
Just reported
From Septerna, Inc.'s results release of November 9, 2026; its quarterly report has since been filed.
Actual
$18.9M
-12% y/y
-29% q/q
Guided
—
No guide given
Actual
-$0.57
Guided
—
No guide given
Actual
-$27.2M
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $18.9M | $21.5M | -12.16% |
| Profit | -$26.6M | $8.2M | -425.34% |
| Profit per share | -$0.57 | $0.18 | -416.67% |
| Free Cash Flow | -$13.9M | $168.8M | -108.23% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Septerna, Inc. reported on November 9, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“We are building momentum across our portfolio, with an upcoming important clinical milestone for SEP-479, our oral PTH1R agonist for hypoparathyroidism, and the selection of SEP-204 as our oral TSHR NAM development candidate for Graves’ disease and thyroid eye disease,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs. The company’s proprietary Native Complex Platform ® is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates. Septerna is advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, both independently and with partners.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Septerna, Inc.’s Item 2.02 8-K filed November 9, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.